US pharma company Pfizer has launched China 's first pay - for - service insurance product , with breast cancer treatment Ibrance Plus , in partnership with PICC Health Insurance and Shanghai MediTrust Health . (NYSE:PFE) launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China. The program is being rolled out in 34 cities , and is available to a maximum of 100 patients with no previous first - line endocrine cancer treatment . Pfizer said those experiencing disease progression or metastasis within the first 126 days of beginning Ibrance treatment , or in combination with an aromatase inhibitor , will be reimbursed with up to 33.5 % of the cost .
US pharma company Pfizer has launched China 's first pay - for - service insurance product , with breast cancer treatment Ibrance Plus , in partnership with PICC Health Insurance and Shanghai MediTrust Health . The program is being rolled out in 34 cities , and is available to a maximum of 100 patients with no previous first - line endocrine cancer treatment . Pfizer said those experiencing disease progression or metastasis within the first 126 days of beginning Ibrance treatment , or in combination with an aromatase inhibitor , will be reimbursed with up to 33.5 % of the cost .